Using organoid technology, adult epithelial stem cells can be expanded in vitro to generate self organizing 3D epithelial structures that closely recapitulate the architecture and cellular composition of the tissue of origin. Because of their strict dependence on Wnt ligands for survival and growth, intestinal organoids have become the tool of choice for in vitro
European regulations might be responsible for lower numbers of advanced therapy clinical trials running in the region when compared to the US and Asia. Europe has historically been a pioneer in advanced therapies, such as cell and gene therapy. Europe was the first region to approve a gene therapy, and it boasts the highest number
Neuromuscular experts with the University of Miami Health System and the Miller School of Medicine will launch a Phase 1/2 clinical trial (NCT04146051) using the CAR-T drug, Descartes-08, to treat patients with generalized myasthenia gravis. Generalized myasthenia gravis (GMG) is a rare disease and a chronic autoimmune condition in which auto-antibodies attack specific proteins at the
Purpose: The primary goal of the present study was to develop the nano-drug consisting of doxorubicin and exosome derived from mesenchymal stem cells, and to explore its effect on osteosarcoma in vitro. Methods: The exosomes were isolated from bone marrow MSCs (BM-MSCs) by an Exosome Isolation Kit. The exosome-loaded doxorubicin (Exo-Dox) was prepared by mixing
Immunotherapy has become a standard treatment approach for several types of cancer, including melanoma. However, tumors can escape immune cell detection even with the use of immunotherapies. In a new study published in Cancer Immunology Research, Moffitt Cancer Center researchers, in collaboration with the University of Miami’s Miller School of Medicine, describe a cellular mechanism that controls tumor cell
Europe has become less competitive than other regions in attracting new ATMP clinical trials. Faster and more streamlined review processes for clinical trials by regulatory authorities are fundamental to increase clinical research and development in Europe. There is considerable country-to-country variability within Europe: the UK has the highest absolute number of new ATMP clinical trials,
Medical science has moved on from the one-size-fits-all approach to the era of personalized medicine. European authorities approved the world’s first-ever gene therapy — GSK’s Strimvelis, a treatment for an inordinately rare inherited disorder characterized by a ravaged immune system, in 2016. So far, the EMA has granted the greatest number of marketing authorizations for
Stem cells of the teeth can contribute to the regeneration of non-dental organs, namely mammary glands. According to a new study from researchers at the University of Zurich, dental epithelial stem cells from mice can generate mammary ducts and even milk-producing cells when transplanted into mammary glands. This could be used for post-surgery tissue regeneration
he Food and Drug Administration has halted a clinical trial of Novartis’ Zolgensma gene therapy due to a safety concern found in an animal study, the company said Wednesday. The hold affects the Novartis (NVS) clinical trial known as STRONG, which was testing a higher dose of Zolgensma administered by spinal injection to older children
The European Commission (EC) has approved a combination regimen of Bavencio (avelumab) injections plus Inlyta (axitinib) tablets for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC), the most common type of kidney cancer. The combination can be used in patients regardless of their predicted prognosis and PD-L1 status. The EC’s decision followed a positive recommendation issued in September by the Committee for Medicinal
